×

RNS Number : 0422J

Croma Security Solutions Group PLC

03 April 2024

 

REACH NON-REGULATORY

3 April 2024

Croma Security Solutions Group Plc

                                                     ("CSSG", "Croma", "the "Company" or the "Group")

NHS Contract Win

Croma Security Solutions Group plc (AIM:CSSG) is pleased to announce the award of a new NHS Trust contract worth approximately £0.4 million to be completed in the current financial year, ending 30 June 2024.

The contract which relates to the installation of new security systems across the hospital, is part of a growing relationship with this NHS Trust. Croma already operates a number of other existing smaller security projects with the Trust, and believes there is potential for further projects.

This contract follows the announcement from 29 January 2024, of the Company being re-awarded a three-year maintenance contract by a separate NHS Trust to cover the security needs of their hospitals. Croma now service several NHS Trust's and healthcare providers and this win reflects Croma's reputation in the healthcare sector for its professional approach and consistently high service levels.

Roberto Fiorentino, Chief Executive Officer, commented:"The business is performing to plan and this recent contract win is part of our growing presence in the healthcare sector. We have focused on delivering transparency and reliability, a combination that is proving attractive to the management teams of NHS Trusts."

 

 

For further information visit www.cssgplc.com or contact:

 

Croma Security Solutions Group Plc                                                       Tel: +44 44 (0)1489 566 166

Roberto Fiorentino, CEO

Teo Andreeva, CFO

 

 

Novella                                                                                                           Tel: +44 (0)203 151 7008

Tim Robertson

Claire de Groot

Safia Colebrook

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAQLLFBZZLLBBB

Close

×

RNS Number : 0366J

Genedrive PLC

03 April 2024

 

genedrive plc

("genedrive" or the "Company")

 

NICE recommends the Genedrive® CYP2C19-ID Kit

Genedrive® CYP2C19-ID test for genotype-guided clopidogrel treatment in the NHS

chosen as the preferred platform for UK point-of-care genotype testing

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance that the Genedrive® CYP2C19-ID test should be used as the point-of-care ("POC") test of choice before clopidogrel administration in the management of Ischemic Stroke ("IS") and Transient Ischaemic Attack ("TIA") patients. 

 

Clopidogrel is an antiplatelet drug used after IS or TIA to reduce the risk of blood clots that can cause further strokes. Clopidogrel is metabolised into its active form by an enzyme encoded by the CYP2C19 gene which in some people has variations that reduce the enzyme's function which means that clopidogrel does not work as well in these people.

 

The Genedrive® CYP2C19-ID point of care genetic test uses a single, non-invasive cheek swab sample, and rapidly identifies six important genetic variants of the CYP2C19 gene, which are instrumental in the loss of metabolism function. The Genedrive® System automatically interprets the information for the clinician, allowing prompt administration of an optimised treatment plan.

 

According to the World Stroke Organization, there are over 77 million people globally who currently have experienced ischaemic stroke and it is estimated by the Stroke Association that there are 100,000 strokes in the UK each year.  Suboptimal response to antiplatelet treatment following stroke is common, affecting about 20%-30% of patients in the general UK population, which increases to about 50%-60% in certain ethnic groups.

 

NICE recommended in the May 2023 draft guidance that people who have just had an IS or TIA should have a CYP2C19 genetic test prior to antiplatelet treatment. Following a public consultation of this draft guidance, which ends on 26 April 2024, final recommendations are expected to be published by NICE on 10 July 2024.The public consultation documents and summary review of NICE's information can be found at:   

https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents

 

The specialist NICE diagnostics assessment committee systematically reviewed the clinical and economic impact of genetic testing, including both laboratory-based and POC tests, concluding that it would be beneficial for people with loss-of-function CYP2C19 alleles to receive alternative antiplatelet treatment to clopidogrel and CYP2C19 genotype testing is also cost effective compared with not testing regardless of which alternative antiplatelet therapy people have.

 

In addition to being dominant in cost effectiveness models, NICE recommends the Genedrive® as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS.  The decision was based on several differentiating features of the Genedrive® technology; (1) its greater coverage of genetic variants compared to the other point-of-care system assessed, permitting increased equitable access to healthcare across ethnic populations, (2) no requirement for cold-chain storage logistics, (3) its ability to integrate with patient electronic healthcare systems.

 

As previously communicated, the Company's ongoing valued long-standing partnership with clinical genetics collaborators in Manchester under the DEVOTE programme will supplement our existing clinical performance data used for UKCA certification and lead to anticipated CE-IVD certification and commercialisation within the European Union, and those additional countries that recognise CE-IVD, in early 2025.  Following the completion of the DEVOTE clinical performance, together with final NICE recommendation due on 10 July 2024, the Company would intend to actively pursue commercialisation in the UK.

 

James Cheek, CEO of genedrive plc, said:"We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for FAST (Face, Arms, Speech, Time) and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect. Clopidogrel is the NICE recommended front line treatment for these types of strokes. However, if you are one of the estimated 20%-30% who are unable to metabolise Clopidogrel effectively you have the opportunity to be identified quickly and given an alternative medication. We are delighted to be part of this change which is in line with our strategy to deliver point-of-care pharmacogenetic testing to positively impact patient outcomes. With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve Food and Drug Administration ("FDA") approval and sales being realised from new customers in 2024 we feel there is growing momentum within the Group's POC  pharmacogenetic testing strategy."

 

Professor Bill Newman, Clinical Head of Division and Senior Lecturer in Clinical Genetics at Manchester University NHS Foundation Trust, said:"The DEVOTE Programme funded by Innovate UK has brought together academic, industry and clinical partners from across Manchester to deliver novel genomic diagnostics to make medicine prescription safer and more effective for patients. We have been delighted to work with genedrive to develop their point of care test which will ensure that rapid results are available to reduce the risk of patients having further strokes."

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 orgenedrive@walbrookpr.com
Anna Dunphy	+44 (0)7876 741 001

 

 

About genedrive plc(http://www.genedriveplc.com). genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. This helps clinicians to quickly access key genetic information that will help them make the right choices over the right medicine or dosage to use for an effective treatment. Based in the UK, the Company is at the forefront of work on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics impacts a medicines ability to work for you. Therefore, by using pharmacogenetics, medicines can be made safer and more effective. The Company has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. This test allows clinicians to make a decision on antibiotic use within 26 minutes; ensuring vital care is delivered with no negative impact on the patient pathway.

 

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCKZGGDKZMGDZM

Close

×

RNS Number : 8680H

Billington Holdings PLC

22 March 2024

 

 

22 March 2024

Billington Holdings plc

 

("Billington", the "Group" or the "Company")

 

£90 million of Contracts Awarded

 

Billington Holdings plc (AIM: BILN), one of the UK's leading structural steel and construction safety solutions specialists, is pleased to announce that the Group has recently been awarded six new contracts with a combined value of circa £90 million.

 

Billington has secured the largest single contract in its trading history to achieve its largest order book to date, materially ahead of the previous record in Q1 2023. The contract wins span a variety of sectors including power generation, manufacturing and retail logistics, and will be delivered nationally over the next 24 months.

 

Mark Smith, Chief Executive Officer of Billington, commented:

 

"The award of these significant contracts is great news for Billington. They are a testament to our Group offering in a challenging trading environment and demonstrates that Billington is a steelwork contractor of choice. The Group currently has a record orderbook and these contracts provide further confidence that Billington will continue to perform well in 2024 and into 2025, further underpinning current market expectations. I look forward to providing further updates at the time of the release of the Group's results for the year ended 31 December 2023 in April 2024."

For further information please contact:

Billington Holdings Plc Mark Smith, Chief Executive Officer Trevor Taylor, Chief Financial Officer	Tel: 01226 340 666
Cavendish Capital Markets Ltd – Nomad and Broker Ed Frisby / Charlie Beeson – Corporate Finance Andrew Burdis – ECM	Tel: 020 7220 0500
IFC Advisory Limited Tim Metcalfe Graham Herring Zach Cohen	Tel: 020 3934 6630 billington@investor-focus.co.uk

 

About Billington Holdings plc

 

Billington Holdings plc (AIM: BILN), one of the UK's leading structural steel and construction safety solutions specialists, is a UK based Group of companies focused on structural steel and engineering activities throughout the UK and European markets. Group companies pride themselves on the provision of high technical and professional standards of service to niche markets with emphasis on building strong, trusted and long-standing partnerships with all of our clients.https://billington-holdings.plc.uk/

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTUAVBRSSUOUAR

Close

×

Neville Registrars are delighted to welcome Franchise Brands plc as the newest addition to its list of client companies.

Franchise Brands plc are a multi-brand franchisor, focused on B2B van-based service, with a presence in 10 countries across the UK, North America and Europe. They are focused on building market-leading businesses primarily via a franchise model and have over 625 franchisees across seven franchise brands and system sales of £350m.

Further information can be found on the Company's website: https://www.franchisebrands.co.uk/ 

Close

×

RNS Number : 6847H

Silver Bullet Data Services Grp PLC

21 March 2024

 

21 March 2024

 

Silver Bullet Data Services Group plc

("Silverbullet", the "Company" or, together with its subsidiaries, the "Group")

 

Contract Wins and Renewals

 

Silverbullet, a provider of AI driven digital transformation services and products, is pleased to announce new contract wins and renewals worth, in aggregate, £1.7 million.

 

Heineken

Silverbullet has secured a renewed contract with Heineken, a Global Dutch multinational brewing company with a presence in over 70 countries and ownership of 165 breweries. As Heineken's trusted data services partner, Silverbullet will serve as a multi-regional resource for first-party data services, overseeing the implementation of a comprehensive first-party customer data strategy and implementation.

 

Silverbullet is working with Heineken to support both business and technical client stakeholders in the design, deployment, execution, and measurement of data-driven consumer experiences, leveraging their existing marketing and advertising technology stacks.

 

Over recent years, Silverbullet has worked with Heineken to develop a Centre for Excellence with respect to its digital marketing transformation, which supports the major operating companies within the Heineken Group globally, including in the UK, USA, Mexico, Brazil, Spain and Ireland.

 

Greene King

In addition, Silverbullet has successfully renewed its 2023 contract and secured a new contract with Greene King, a leading pub retailer and brewer in the UK. Silverbullet is collaborating closely with Greene King to deliver transformative solutions, leveraging AI and digital strategies to enhance their operations.

 

Silverbullet is working with Greene King to implement technology that enables enhanced personalisation for customers and supports the growth of its digital transformation programme.

 

Silverbullet will be providing architects, engineers and subject matter experts to ensure that the existing marketing technology is well integrated within Greene King's digital ecosystem, as well as Greene King's brick and mortar real estate, with the objective of delivering highly personalised communications to customers by leveraging profile and behavioural data to improve customer experience.

 

These contracts see Silverbullet's engagement with Greene King expand into new departments and initiatives, cementing the work done in 2023 by ensuring new teams and stakeholders invest in the programme Silverbullet implemented last year.

 

Ian James, Chief Executive Officer of Silverbullet, commented:

"These contract wins underscore the rapid advancement of marketing transformation driven by first-party data across the global brand landscape. Being entrusted by our multinational clients to lead their upcoming growth phases serves as robust validation that our strategy is being well adopted as we focus on our clients' intelligent data utilisation in the privacy-centric era. These wins underscore Silverbullet's commitment to driving digital innovation and reinforcing its position as a premier partner in AI-driven digital transformation."

 

 

For further information please contact:

Silverbullet		via IFC
Ian James (CEO)
Strand Hanson Limited – Financial and Nominated Adviser		0207 409 3494
James Spinney / James Bellman / Robert Collins
Oberon Capital – Joint Broker		0203 179 5344
Mike Seabrook / Chris Crawford / Nick Lovering
CMC Markets – Joint Broker		0203 003 8632
Douglas Crippen
IFC Advisory		020 3934 6630
Graham Herring / Tim Metcalfe / Florence Chandler		07793 839 024

 

About Silverbullet

Silverbullet's proprietary 4D AI advertising solution is designed to help advertisers target consumers in a "post cookie world". The product is a natural extension to its existing services business which already serves a blue-chip client base such as Mars, Heineken, Sony, Omnicom Group, Greene King and ITV amongst many others. The removal of third-party cookies has already been implemented by web browsers such as Firefox and Safari, with Google expected to phase out the use of cookies in 2024. 

 

Headquartered in London, the Group employs 80+ data specialists across five regions across the globe, including, the UK, Italy, Australia, USA and Latin America. The Group continues to look at other opportunities for expansion worldwide.

 

The Company has an established and growing services business with significant accumulated industry experience and a proven track record of delivering strategic digital transformation and activation services to its clients. The majority of the Board have held senior positions at global software companies and have significant industry experience across data engineering, SAAS product development and marketing.

 

The Group has close technical and commercial partnerships with multiple global technology providers, all of which have existing sales channels and are already delivering to clients.

 

The Group has established a strategic partnership and an entity with Local Planet, a scaled network of over 60 agencies across the globe.  Local Planet Data Services Limited was established in December 2020 and presents a significant opportunity to provide data services and the 4D product to the Local Planet agency network.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTFLFEDVAIIFIS

Close

×

RNS Number : 5899H

Netcall PLC

20 March 2024

 

RNS Reach

20 March 2024 

 

NETCALL PLC

("Netcall", the "Company", or the "Group")

£7.6m Liberty platform Contract Renewal

Leading transportation company grows and broadens Liberty cloud subscription

Netcall plc (AIM: NET), the leading provider of intelligent automation and customer engagement software, is pleased to announce it has successfully secured a new £7.6m five-year contract renewal with a leading transportation company, (the "Customer") for Liberty cloud services.

The contract extension, which commences on 1st April 2024, represents a £0.4m uplift per annum from the original contract. As part of the renewal, the Customer is re-licencing the usage of Netcall's Liberty Create Low-code platform and opting to incorporate additional platform capabilities such as Liberty Robotic Process Automation (RPA) solutions to help drive rapid process automation and improve overall efficiency and effectiveness within the business.

Having already built and deployed live applications using Netcall's platform, the contract renewal allows greater scope for the Customer to grow their usage of the platform and deliver their digital transformation ambitions.

James Ormondroyd, CEO of Netcall plc commented:"We are delighted to have the opportunity to continue supporting this customer with their digital strategy for a further five years. This significant renewal highlights the value proposition of the Liberty platform to our customers, as well as the broad applicability and tangible results that our digital toolkit delivers across a range of market segments."

 

Enquiries:

 

Netcall plc	Tel. +44 (0) 330 333 6100
James Ormondroyd, CEO Henrik Bang, Non-Executive Chairman Richard Hughes, CFO
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)	Tel. +44 (0) 20 7523 8000
Simon Bridges / Andrew Potts
Singer Capital Markers (Joint Broker) Harry Gooden / Asha Chotai	Tel +44 (0) 20 7496 3000
Alma Strategic Communications	Tel. +44 (0) 20 3405 0205
Caroline Forde / Hilary Buchanan / Robyn Fisher

 

About Netcall:

Netcall's Liberty software platform with Intelligent Automation and Customer Engagement solutions helps organisations digitally transform their businesses faster and more efficiently, empowering them to create a leaner, more customer-centric organisation.  

Netcall's customers span enterprise, healthcare and government sectors. These include two-thirds of the NHS Acute Health Trusts and leading corporates including Legal and General, Lloyds Banking Group, Aon and Nationwide Building Society.

For further information, please go to www.netcall.com.

 

About Reach announcements

This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAJMMPTMTATMPI

Close

×

RNS Number : 9503G

Biome Technologies PLC

15 March 2024

 

 

15 March 2024

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Contract win for Stanelco RF Division

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, is pleased to announce that its RF Technologies division (www.stanelcorftechnologies.com) has been awarded a further contract win.  The contract has a revenue value of £536,000 to supply two radio frequency welding systems (the "Systems") for use by an international corporation in the medical supply sector.

 

The Systems will use a modular machine platform which integrates automation and RF welding. They will be built and tested at the Company's Marchwood, UK, facility and subsequently combined with other production line equipment supplied by the end-customer's chosen contractor before final installation in a UK facility. Completion of the Systems is scheduled within the 2024 financial year, with stage payments being received against milestones during the contract.

 

This contract is one of the opportunities for the RF Technologies Division indicated in our 11 March 2024 announcement and will contribute towards our Group expectations for 2024.

 

Paul Mines, CEO, commented, "This important order results from the division's ongoing strategy of diversification beyond its traditional strength into new high-value medical market areas. The division continues to work on further potential opportunities and we remain confident in bringing another of these opportunities to a similar conclusion in the coming months."

 

-Ends-

For further information please contact:
Biome Technologies plc Paul Mines, Chief Executive Officer
Rob Smith, Chief Financial Officer
www.biometechnologiesplc.com	Tel: +44 (0) 2380 867 100
Allenby Capital
David Hart/Alex Brearley (Nominated Adviser) Kelly Gardiner/Tony Quirke (Sales and Corporate Broking)
www.allenbycapital.com	Tel: +44 (0) 20 3328 5656

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics and RF Technologies.

 

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The division's mission is to produce bioplastics that challenge the dominance of oil- based polymers.

 

RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.comwww.biomebioplastics.comandwww.thinkbioplastic.comwww.stanelcorftechnologies.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTDZLFFZXLEBBB

Close

×

RNS Number : 7459G

Smarttech247 Group PLC

14 March 2024

 

Reach Announcement

14 March 2024

Smarttech247 Group PLC

 

("Smarttech247", the "Group" or the "Company")

 

Smarttech247 Secures New Three-Year Contract worth c. €1 million

 

Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, is pleased to announce it has secured a new contract with a global packaging company, worth approximately €1 million over three years.

 

The agreement, with a new client, utilises both Smarttech247's VisionX platform as well as NoPhish, underscoring their versatility and advanced capabilities. VisionX is Smarttech247's flagship AI-enhanced Managed Detection and Response (MDR) platform, designed to safeguard both Information Technology (IT) and Operational Technology (OT) infrastructures and its NoPhish email security tool offers instant feedback to the user based on analysis algorithms to evaluate the content and legitimacy of reported emails. In an era where the convergence of IT and OT systems is increasingly critical for industrial and manufacturing sectors, this partnership represents a strategic and forward-thinking approach to cybersecurity.

The VisionX MDR platform leverages sophisticated AI and machine learning algorithms to offer real-time threat detection, rapid incident response, and continuous monitoring whilst NoPhish takes proactive measures by automatically removing emails from the user's inbox which are deemed suspicious or malicious. By extending its protection to both IT and OT domains as well as emails, these platforms ensure our clients are guarded against diverse and evolving cyber threats across all digital touchpoints.

 

Raluca Saceanu, CEO of Smarttech247, commented:

 

"We are delighted to win this new contract, which serves as a strong endorsement for both our AI-enhanced VisionX MDR platform's capability and our NoPhish email security tool to secure both IT and OT environments.

 

"This collaboration ensures our client will have a robust defence mechanism for its extensive digital operations, encompassing everything from corporate data to critical operational processes and email security.

 

"This agreement with a new client is a significant milestone for us and we remain committed to supporting all our existing and new clients on their journey towards a secure and resilient digital infrastructure."

 

 

– Ends –

For further information please contact:

Smarttech247 Group PLC	Tel: +353 21 206 6033
Ronan Murphy, Executive Chairman Raluca Saceanu, Chief Executive Officer Nicholas Lee, Finance Director
SPARK Advisory Partners Limited – Nominated Adviser	Tel: + 44 (0) 20 3368 3550
Mark Brady / Adam Dawes
Shard Capital – Joint Broker	Tel: +44 (0) 20 7186 9900
Damon Heath
Fortified Securities – Joint Broker	Tel: +44 7493 989014
Guy Wheatley, CFA
Yellow Jersey PR Sarah Hollins / Annabelle Wills / Bessie Elliot	Tel: +44 (0) 20 3004 9512

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only/non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

About Smarttech247

Smarttech247 is a multi-award winning automated MDR (Managed Detection & Response) company. Its platform is trusted by international organisations and provides threat intelligence with managed detection and response to provide actionable insights, 24/7 threat detection, investigation and response.

The Group's services are geared towards proactive prevention and it achieves this by utilising the latest in cloud, big data analytics and machine learning, along with an experienced incident response team. In recognition of its innovative technology, Smarttech247 was named by Chambers Ireland InBusiness Recognition Awards as Cyber Security Company of the Year 2023.

Smarttech247's offices are located in Ireland, United Kingdom, Romania, Poland and the USA. The Company was admitted to trading on AIM on 15 December 2022.

For further information please visit www.smarttech247.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAQKNBQQBKDQND

Close

×

RNS Number : 9099F

Intuitive Investments Group plc

07 March 2024

 

7 March 2024 

 

Intuitive Investments Group plc

 

Hui10 contract win to roll outits technology platform to 2,000 Lottery Shops in 2024

 

Intuitive Investments Group plc (SFS: IIG) ("IIG" or the "Company"), the closed-end investment company focussed on fast growing and high potential opportunities in the Technology, Life Sciences and Healthcare sectors,announces the following update in respect of its largest single investment, Hui10 Inc. ("Hui10"). Hui10 is a technology company with interests in two operating businesses, Huishi Dehua and Huishi Chunyuan ("Lucky World"), involved in the digital transformation of the Chinese lottery.

 

The Chinese lottery is currently a paper tickets onlyoperation being sold from lottery only shops, with limited distribution in relation to the size of the addressable market. Hui10 is modernising China's lottery through its proprietary fully integrated technology platforms.  

 

The first step in this journey to digitalise the Chinese lottery is the implementation of Lucky World's HongBao (Red Envelope) technology. HongBao enables UnionPay business clients, including banks, mobile phone network operators, insurance companies, utilities, airlines, travel companies, food chains, retailers and merchants, to run promotion and marketing campaigns at minimal cost, direct to their existing users and to attract new customers by purchasing HongBao lottery from Hui10. Users receive and view their HongBao on their smart device and use it to pay for lottery tickets via the UnionPay POS terminals deployed to the lottery shops. This is a critical first stage in establishing a new way to pay for lottery tickets while also commencing the roll out of the Hui10 UnionPay infrastructure into the dedicated lottery stores to ensure the stores are e-ticket ready.

 

Hui10 has secured contracts with Hebei Sports Lottery Centre. Under the terms of these contracts, Hui10 will deploy its UnionPay POS terminals into 2,000 lottery shops in Hebei Province by the end of 2024. These POS terminals include Lucky World's technology and are the only POS terminals capable of processing the HongBao and credit the lottery shopkeeper's account instantly. For IIG, this represents the next important stage of Hui10's strategy to increase lottery play participation rates across China.

 

Following a successful initial rollout across lottery shops in Hebei and subject to the entering into of a new contract, Hui10 will look to continue the rollout of HongBao across the entire estate of c.175,000 Lottery shops across China.

 

Hui10 has developed a technology platform which is integrated into China UnionPay's clearing and settlement system as a mini program. UnionPay is the largest card organisation in the world, with over 9.6 billion payment cards issued, 2.5 billion active cards, over 450 million QuickPassPay APP users and 35 million POS terminals.

 

Enquiries:

 

Intuitive Investments Group plc	www.iigplc.com
Sir Nigel Rudd, Non-Executive Chairman Robert Naylor, CEO Giles Willits, CIO	Via FTI Consulting
Cavendish Capital Markets Limited James King / William Talkington / Daniel Balabanoff	+44 (0) 20 7397 8900
SP Angel Corporate Finance LLP – Financial Adviser	+44 (0) 20 3470 0470
Jeff Keating / David Hignell / Kasia Brzozowska
FTI Consulting	+44 (0) 20 3727 1000
Jamie Ricketts / Valerija Cymbal / Jemima Gurney	IIG@fticonsulting.com

 

 

About Intuitive Investments Group plc & Hui10

 

IIG is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Technology and Life Sciences businesses operating predominantly in the UK, continental Europe, the US and APAC, utilising the Board's experience to seek to generate capital growth over the long term for shareholders.

 

Hui10 is a technology company with interests in two operating businesses, Huishi Dehua and Huishi Chunyuan ('Lucky World'), involved in the digital transformation of the Chinese lottery. Huishi Dehua enables the market expansion of the Chinese lottery through its proprietary technology platform. Huishi Dehua is integrated into China's national card settlement system and payment platform, UnionPay. Hui10 holds a 33% share in Huishi Dehua. Lucky World is an ecommerce platform which provides China's existing lottery shops access to a wider fast-moving consumer goods product offering. Hui10 owns 60% of Lucky World.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUPURWWUPCPWQ

Close

×

RNS Number : 4997E

itim Group PLC

27 February 2024

 

27 February 2024

 

itim Group plc

 

("itim" or "the Company" and together with its subsidiaries "the Group")

 

Contract Win with QUIZ clothing

 

itim Group plc, a SaaS based technology company that enables store-based retailers to optimise their businesses to improve financial performance, is pleased to announce the contract win and go live of itim's Omni channel retail platform for QUIZ clothing, a fashion retailer specialising in occasion wear and dressy casual wear with 73 stores and 274 concessions in the UK.

 

This five year multi-million-pound contract is a significant achievement for itim, as QUIZ is the first fashion retailer in its customer portfolio to implement the end-to-end retail platform as well as its new wholesale module.  The addition of the wholesale module and fashion capabilities completes The Retail Suite product development and will enable itim to offer our platform to other fashion retailers. QUIZ will utilise the platform to drive omni-channel customer journeys online, via an app and in store, alongside driving its core retail and wholesale businesses.

 

itim's Retail Suite product, soon to be rebranded as UNIFY, provides its customers with a full omni-channel offering which allows retailers to drive sales and profitability by adopting the principles of Unified Retailing.

 

Ali Athar, Chief Executive Officer, commented:

"We are delighted to have been selected by Quiz to work with them to enhance and expand their omni-channel capabilities. This important contract demonstrates the breadth and depth of our platform and our ability to add value in the highly customer-centric fashion sector."

 

The Company also expects to provide a general trading update for the period ended 31 December 2023, shortly.

 

 

Enquiries:

 

Itim Group plc	Ali Athar, CEO Ian Hayes CFO	0207 598 7700
WH Ireland (NOMAD & Broker)	Katy Mitchell Harry Ansell Darshan Patel	0207 220 1666
IFC Advisory	Graham Herring Florence Chandler	0207 3934 6630

 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

ABOUT ITIM

itim was established in 1993 by its founder, and current Chief Executive Officer, Ali Athar. itim was initially formed as a consulting business, helping retailers effect operational improvement. From 1999 the Company began to expand into the provision of proprietary software solutions and by 2004 the Company was focused exclusively on digital technology. itim has grown both organically and through a series of acquisitions of small, legacy retail software systems and associated applications which itim has redeveloped to create a fully integrated

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTQQLFLZLLFBBV

Close